Subtype
Thyroid Gland Neoplasm
CI-CAN-00001600Explore in graph →
Non-malignant189 active trials10 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001600Explore in graph →
Clinical trials
891 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | active not recruiting | Phase 2 | 6,452 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT06991738 | 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer | not yet recruiting | Phase 1 / Phase 2 | 18 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH |
| 1 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT04216732 | Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management | recruiting | — | 2,030 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07124000 | DESTINY-PANTUMOUR04(DP-04) | recruiting | — | 100 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07142005 | Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer | recruiting | — | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02293954 | Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer | active not recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06475989 | Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer | recruiting | Phase 3 | 264 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07822880 | A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India | not yet recruiting | Phase 4 | 30 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT01005654 | Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms | recruiting | — | 2,415 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01660984 | Natural History Study of Children and Adults With Medullary Thyroid Cancer | active not recruiting | — | 105 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03765333 | GETNE Registration of Thyroid Cancer | recruiting | — | 20 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07006727 | Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors | recruiting | Phase 1 | 116 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 22, 2026 | clinicaltrials |
| NCT07428057 | Postoperative Hypocalcemia After Thyroidectomy | recruiting | — | 600 | Minia UniversityOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06507878 | Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.(GRASSROOT) | recruiting | — | 459 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04544111 | PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | active not recruiting | Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04467021 | Cancer and Blood Pressure Management, CARISMA Study | active not recruiting | N/A | 61 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04927416 | The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer | recruiting | Phase 2 | 54 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | recruiting | Phase 1 / Phase 2 | 554 | Institut de Recherches Internationales ServierOTHER | 10 | Sep 16, 2026 | clinicaltrials |
| NCT06235216 | Sacituzumab govitEcan in THYroid Cancers(SETHY) | recruiting | Phase 2 | 42 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07140757 | Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers | recruiting | — | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07823439 | Pattern and Surgical Outcome of Papillary Thyroid Cancer at Sohag University Hospitals | not yet recruiting | — | 30 | Sohag UniversityOTHER | 0 | Sep 16, 2026 | clinicaltrials |
| NCT07823543 | Educational Videos for Thyroid Surgery Patient | not yet recruiting | N/A | 400 | West China HospitalOTHER | 0 | Sep 16, 2026 | clinicaltrials |
| NCT04104529 | Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department(BCB RIV) | recruiting | N/A | 350 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06796348 | Radiofrequency Ablation Versus Hemithyroidectomy for Small Thyroid Cancers | recruiting | N/A | 88 | University of AarhusOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT01709292 | Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer | active not recruiting | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04285476 | Predictive Value of microRNA in Thyroid Cytologies of Undetermined Type(PREDICYTHY) | active not recruiting | N/A | 71 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07218315 | Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma | recruiting | N/A | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT03647358 | Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma | recruiting | Phase 1 | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05557045 | A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | active not recruiting | Phase 1 | 98 | Jazz PharmaceuticalsINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07707401 | Effectiveness of WeChat-Supported Neck Rehabilitation Exercises on Early Recovery After Thyroidectomy | recruiting | N/A | 200 | Shanghai 6th People's HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812779 | Thyroid Health Outcomes Registry for Surgery(THORS) | not yet recruiting | — | 3,000 | Pirogov Russian National Research Medical UniversityOTHER | 0 | Sep 10, 2026 | clinicaltrials |
| NCT03841617 | The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer | recruiting | Phase 2 | 30 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05119296 | Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer | active not recruiting | Phase 2 | 9 | Saad A KhanOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06902376 | XL092 and Cemiplimab in BRAF WT Thyroid Cancer(NEO-COMBATXL) | recruiting | Phase 1 | 12 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06959511 | Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery | recruiting | Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07459283 | The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors | recruiting | Early Phase 1 | 10 | FindCure Biosciences (ZhongShan) Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | recruiting | — | 2,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07485569 | Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial(REPOTHYROID-II) | active not recruiting | Phase 1 | 10 | Radboud University Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05355701 | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | active not recruiting | Phase 1 | 103 | PfizerINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | active not recruiting | Phase 1 | 148 | PfizerINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT07690839 | Pre-Clinic Visit Online Education for Thyroid Cancer | not yet recruiting | N/A | 60 | Cedars-Sinai Medical CenterOTHER | 0 | Sep 1, 2026 | clinicaltrials |
| NCT00001160 | Studies on Tumors of the Thyroid | recruiting | — | 2,500 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT02152995 | Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer | active not recruiting | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | active not recruiting | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT07776262 | Safety and Efficacy of Cryoablation for Thyroid Tumors | recruiting | N/A | 108 | Yukun LuoOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07777536 | Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer | recruiting | Phase 2 | 72 | Fudan UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06931743 | The Application of Electrical Stimulation in Postoperative Pain Management of Thyroid Surgery | recruiting | N/A | 668 | Xiaonan HuangOTHER | 1 | Aug 19, 2026 | clinicaltrials |
Data updated 8 hours agoSource updated Sep 29, 2026source: clinicaltrials